Equity Capital Markets

Company · CIK 1658551

Amylyx Pharmaceuticals, Inc.

CIK1658551 (SEC EDGAR)
Industry (SIC)2834 — Pharmaceutical Preparations
Incorporated inDE
Business addressMA
ListedAMLX (Nasdaq)
First annual or quarterly report2022-03-31

Offerings

5 registrations
RegistrationLabel and statusFirst filedLast eventFilings
333-293956
ShelfEffective
 2026-03-032026-08-203
333-285525
ShelfEffective
 2025-03-042025-09-104
333-270505
ShelfEffective
 2023-03-132025-01-103
333-267730
Registered companyFinal prospectus
 2022-10-042022-10-073
333-261703
IPOFinal prospectus
 2021-12-162022-01-104

Filings

19
FiledFilingRegistrationAccession
2026-08-20424B5Shelf takedown 333-2939560001193125-26-359416
2026-08-18424B5Shelf takedown 333-2939560001193125-26-355696
2026-03-03S-3ASRShelf registered 333-2939560001193125-26-086735
2025-09-10424B5Shelf takedown 333-2855250001193125-25-200144
2025-09-09424B5Shelf takedown 333-2855250001193125-25-199270
2025-03-26EFFECTDeclared effective 333-2855259999999995-25-000794
2025-03-04S-3Shelf registered 333-2855250001193125-25-044854
2025-01-10424B5Shelf takedown 333-2705050001193125-25-004537
2025-01-10424B5Shelf takedown 333-2705050001193125-25-004002
2023-03-13S-3ASRShelf registered 333-2705050001193125-23-069187
2022-10-07424B4Final prospectus 333-2677300001193125-22-259634
2022-10-06EFFECTDeclared effective 333-2677309999999995-22-002975
2022-10-04S-1Registration filed 333-2677300001193125-22-257577
2022-08-24DRSDraft made public 377-063290000950123-22-009682
2022-01-10424B4Final prospectus 333-2617030001193125-22-005621
2022-01-06EFFECTDeclared effective 333-2617039999999995-22-000076
2022-01-03S-1/AAmendment 333-2617030001193125-22-000260
2021-12-16S-1Registration filed 333-2617030001193125-21-359405
2021-04-26DRSDraft made public 377-047290000950123-21-004949

All filings of this company · CSV